Autonomix Medical Inc(AMIX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 4 at 8:35 AM ET (Korea 11/4 22:35)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -46.48 | Insider Own | 5.9% | Shs Outstand | 2.0M | Perf Week | -19.81% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.8M | Perf Month | -53.11% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -2.62 | Inst Own | 2.6% | Short Float | 3.21% | Perf Quarter | -86.28% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | 6.66% | Short Ratio | 0.02 | Perf Half Y | -79.14% |
| Sales | 0.00B | P/B | 0.28 | EPS next 5Y | 69.24% | ROA | -248.22% | Short Interest | 0.06M | Perf YTD | -85.63% |
| Book/sh | 5.83 | P/C | 0.94 | EPS past 3/5Y | -3.02% 35.84% | ROE | -315.99% | 52W High | -94.9% ($32.55) | Perf Year | -92.17% |
| Cash/sh | 1.77 | P/FCF | - | Sales past 3/5Y | - | ROIC | -509.36% | 52W Low | -1.19% ($1.68) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 64.78% | Gross Margin | - | Volatility(W/M) | 9.6% 7.07% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.85 | EPS Q/Q | 77.77% | Profit Margin | - | RSI (14) | 18.29 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.85 | Sales Q/Q | - | SMA20 | -34.51% ($2.53) | Beta | -0.72 | Target Price | $6 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -54.89% ($3.68) | Rel Volume | 0.01 | Prev Close | $1.68 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -75.23% ($6.7) | Avg Volume(3M) | 2.98M | Price | $1.66 |
| IPO | 2024/1/29 | Option/Short | No/Yes | Trades | 346 | Volume | 42,988 | Change | -1.19% |
🩺 A US micro-cap clinical-stage medical device company developing catheter-based nerve sensing and blocking technology. Using microchip sensing array antennas to precisely measure nerve signals, the company aims to apply this technology to nerve-related treatments, such as pain relief for pancreatic cancer patients.
Over the past 1 year, on the lower side
95% below its 1-year high.
Traded less than usual. That is 1% of its average volume.
AMIX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +69.2% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.6%.
Tap to view numbers
It ranks #131 of 140 in the industry
Based on market cap of $3M.
VVOS#129 Vivos Therapeutics Inc $4M PER - 
CODX#130 Co-Diagnostics Inc $3M PER - AMIX#131 Autonomix Medical Inc $3M PER - 
NUWE#132 Nuwellis Inc $3M PER - 
AIDX#133 20/20 Biolabs Inc $3M PER - 
FAQ
What kind of company is AMIX?
AMIX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of AMIX?
The market cap of AMIX is approximately $3M, ranking 5,715 within its sector.
What is the 52-week high and low for AMIX?
AMIX has recorded a 52-week high of $32.55 and a low of $1.68.
